<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03444480</url>
  </required_header>
  <id_info>
    <org_study_id>RMZL-PIb</org_study_id>
    <nct_id>NCT03444480</nct_id>
  </id_info>
  <brief_title>A Phase Ⅰb Study of Remimazolam Tosylate in Healthy Volunteers</brief_title>
  <official_title>A Phase Ⅰb Study Evaluating the Pharmacokinetic,Safety and Efficacy of Remimazolam Tosylate in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Pharmacokinetics/Pharmacodynamics and safety of
      Remimazolam Tosylate in healthy volunteers after loading/maintenance dose regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Study the Pharmacokinetics/Pharmacodynamics of Remimazolam Tosylate in healthy
           volunteers after loading/maintenance dose regimen.

        2. Study the reversal effect and time required of Flumazepine on Rimazolam'effect.

        3. Study the Safety of Remimazolam Tosylate in healthy volunteers after loading/maintenance
           dose regimen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2014</start_date>
  <completion_date type="Actual">August 16, 2014</completion_date>
  <primary_completion_date type="Actual">August 16, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Remimazolam in human plasma.</measure>
    <time_frame>From prior to study drug injection until 4 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of Remimazolam in human plasma.</measure>
    <time_frame>From prior to study drug injection until 4 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of M01 in human plasma.</measure>
    <time_frame>From prior to study drug injection until 4 hours post-dose</time_frame>
    <description>M01 is the main metabolite of Remimazolam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of M01 in human plasma.</measure>
    <time_frame>From prior to study drug injection until 4 hours post-dose</time_frame>
    <description>M01 is the main metabolite of Remimazolam</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety by measurement of Adverse Events.</measure>
    <time_frame>From start of study drug injection to patient discharge (approx. 2 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Remimazolam Tosylate 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start， 0.5 mg Flumazenil is administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remimazolam Tosylate 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start time,0.5ml placebo is administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam Tosylate</intervention_name>
    <description>Initial dose plus supplemental doses</description>
    <arm_group_label>Remimazolam Tosylate 1</arm_group_label>
    <arm_group_label>Remimazolam Tosylate 2</arm_group_label>
    <other_name>HR7056</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥18 and ≤55 years.

          -  Weight range 50 to 100 kg and body mass index (BMI) 18 to 26 kg/m2.

          -  Willing and able to comply with the requirements of the protocol.

          -  Provide written informed consent to participate in the study.

        Exclusion Criteria:

          -  Abnormal results of physical or laboratory examination with clinical significance

          -  With a history of laboratory results that show the presence of hepatitis B surface
             antigen (HBs Ag), hepatitis C antibody (HCV Ab), or human immunodeficiency virus
             (HIV).

          -  With evidence of uncontrolled renal, hepatic, central nervous system, respiratory,
             cardiovascular, or metabolic dysfunction, in the opinion of the investigator or
             medical monitor.

          -  Subject with clinically significant abnormalities in baseline 12-lead
             electrocardiogram (ECG) or vital signs（SBP &lt;90 mmHg or &gt;140 mmHg，DBP &lt;50 mmHg or &gt;90
             mmHg；Hr &lt;50 bpm or &gt;100 bpm；SpO2 &lt;95%）.

          -  Has a known sensitivity to benzodiazepines, flumazenil, or anesthetic agents, or a
             medical condition such that these agents are contraindicated.

          -  Receipt of other medication within 14 days of the first study day.

          -  Blood donation greater than 200 ml or participation in a clinical study of an
             unlicensed drug in the previous 3 months.

          -  History of smoking or alcohol abuse within 6 months of screening.

          -  History of grapefruit juice or any other foods affect the activity of cytochrome P450
             3A4（CYP3A4） within 7 days of screening.

          -  Pregnant,lactating.

          -  Mallampati score ≥3.

          -  Patients who in the opinion of the investigator may not be able to comply with the
             requirements of the study are not eligible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pei Hu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

